KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Free Cash Flow: 2018-2025

Historic Free Cash Flow for Aurinia Pharmaceuticals (AUPH) over the last 10 years, with Sep 2025 value amounting to $44.4 million.

  • Aurinia Pharmaceuticals' Free Cash Flow rose 161.95% to $44.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $119.9 million, marking a year-over-year increase of 327.15%. This contributed to the annual value of $44.1 million for FY2024, which is 229.05% up from last year.
  • According to the latest figures from Q3 2025, Aurinia Pharmaceuticals' Free Cash Flow is $44.4 million, which was up 0.55% from $44.1 million recorded in Q2 2025.
  • In the past 5 years, Aurinia Pharmaceuticals' Free Cash Flow ranged from a high of $44.4 million in Q3 2025 and a low of -$54.6 million during Q1 2021.
  • Over the past 3 years, Aurinia Pharmaceuticals' median Free Cash Flow value was $14.0 million (recorded in 2023), while the average stood at $9.1 million.
  • Per our database at Business Quant, Aurinia Pharmaceuticals' Free Cash Flow tumbled by 1,689.33% in 2021 and then spiked by 623.31% in 2024.
  • Quarterly analysis of 5 years shows Aurinia Pharmaceuticals' Free Cash Flow stood at -$25.9 million in 2021, then skyrocketed by 139.80% to $10.3 million in 2022, then skyrocketed by 35.84% to $14.0 million in 2023, then skyrocketed by 114.50% to $30.1 million in 2024, then surged by 161.95% to $44.4 million in 2025.
  • Its Free Cash Flow stands at $44.4 million for Q3 2025, versus $44.1 million for Q2 2025 and $1.3 million for Q1 2025.